Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy

Conclusions Once-daily 50-mg ipragliflozin enabled a 30% dose reduction of insulin by Week 24 compared with baseline. No major safety concerns were raised.Clinical Trial RegistrationClinicalTrials.gov (NCT02847091)

Source: Clinical Drug Investigation - September 23, 2019 Category: Drugs & Pharmacology Source Type: research